{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:06:13Z","timestamp":1786417573496,"version":"build-2736575974"},"reference-count":58,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals International, Inc., USA.","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>The Short Bowel Syndrome (SBS) Registry (NCT01990040) is a multinational real-world study evaluating the long-term safety of teduglutide in patients with SBS and intestinal failure (SBS-IF) in routine clinical practice. This paper describes the study methodology and baseline characteristics of adult patients who have (ever-treated) or have never (never-treated) received teduglutide. A total of 1411 adult patients (679 ever-treated; 732 never-treated) were enrolled at 124 sites across 17 countries. The mean (standard deviation [SD]) age at enrollment was 55.4 (15.46) years, and 60.2% of patients were women. Crohn\u2019s disease was the most common cause of major intestinal resection in both ever-treated (34.1%) and never-treated patients (20.4%). A similar proportion of ever-treated and never-treated patients had a prior history of colorectal polyps (2.7% vs. 3.6%), whereas proportionally fewer ever-treated patients reported a history of colorectal cancer (1.8% vs. 6.2%) or any malignancy (17.7% vs. 30.0%) than never-treated patients. Never-treated patients received a numerically greater mean (SD) volume of parenteral nutrition and\/or intravenous fluids than ever-treated patients (12.4 [8.02] vs. 10.1 [6.64] L\/week). Ever-treated patients received a mean teduglutide dosage of 0.05 mg\/kg\/day. This is the first report of patient baseline characteristics from the SBS Registry, and the largest cohort of patients with SBS-IF to date. Overall, ever-treated and never-treated patients had similar baseline characteristics. Differences between treatment groups may reflect variations in patient selection and degree of monitoring.<\/jats:p>","DOI":"10.3390\/nu16152513","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T11:34:20Z","timestamp":1722512060000},"page":"2513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry"],"prefix":"10.3390","volume":"16","author":[{"given":"Gabriel E.","family":"Gondolesi","sequence":"first","affiliation":[{"name":"Intestinal Failure, Rehabilitation and Transplant Unit, Hospital Universitario Fundaci\u00f3n Favaloro, Buenos Aires C1044AAA, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-8348","authenticated-orcid":false,"given":"Ulrich-Frank","family":"Pape","sequence":"additional","affiliation":[{"name":"Asklepios Klinik St. Georg, Asklepios Medical School, 20099 Hamburg, Germany"},{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9 University Medicine Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0307-9378","authenticated-orcid":false,"given":"Joel B.","family":"Mason","sequence":"additional","affiliation":[{"name":"Tufts Medical Center, Tufts University, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johane P.","family":"Allard","sequence":"additional","affiliation":[{"name":"Toronto General Hospital, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-8330","authenticated-orcid":false,"given":"Loris","family":"Pironi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"},{"name":"Centre for Chronic Intestinal Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda N\u00faria Virgili","family":"Casas","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren K.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"NYU Langone Medical Center, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Joly","sequence":"additional","affiliation":[{"name":"H\u00f4pital Beaujon, University of Paris Cit\u00e9, 92110 Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasan","family":"Sabrdaran","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinggao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kohl-Sobania","sequence":"additional","affiliation":[{"name":"Outpatient Clinic, Pediatric Emergency Department, University Hospital Schleswig-Holstein, 23538 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-7030","authenticated-orcid":false,"given":"Yi-Wen","family":"Huang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9680-6938","authenticated-orcid":false,"given":"Palle B.","family":"Jeppesen","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5223\/pghn.2019.22.4.303","article-title":"Short bowel syndrome as the leading cause of intestinal failure in early life: Some insights into the management","volume":"22","author":"Goulet","year":"2019","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.clnu.2023.07.019","article-title":"ESPEN guideline on chronic intestinal failure in adults\u2014Update 2023","volume":"42","author":"Pironi","year":"2023","journal-title":"Clin. Nutr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.cgh.2022.05.032","article-title":"AGA Clinical Practice Update on Management of Short Bowel Syndrome: Expert Review","volume":"20","author":"Iyer","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1007\/s00595-022-02469-9","article-title":"Etiologies and treatments of chronic intestinal failure-short bowel syndrome (SBS) in Japanese adults: A real-world observational study","volume":"52","author":"Mizushima","year":"2022","journal-title":"Surg. Today"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clnu.2009.04.022","article-title":"ESPEN guidelines on parenteral nutrition: Gastroenterology","volume":"28","author":"Cabre","year":"2009","journal-title":"Clin. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1002\/ncp.10978","article-title":"Short bowel syndrome: Complications and management","volume":"38","author":"Bering","year":"2023","journal-title":"Nutr. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.clnu.2024.05.013","article-title":"Life on the line\u2014Incidence and management of central venous catheter complications in intestinal failure","volume":"43","author":"Jahns","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_8","first-page":"1759","article-title":"Glucagon-like peptide 2","volume":"86","author":"Drucker","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","first-page":"E1050","article-title":"Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2","volume":"272","author":"Brubaker","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_11","unstructured":"Gattex\u00ae Full Prescribing Information, Shire-NPS Pharmaceuticals, Inc.. Available online: https:\/\/www.shirecontent.com\/PI\/PDFS\/Gattex_USA_ENG.pdf."},{"key":"ref_12","unstructured":"European Medicines Agency, EMA (2024, April 18). Revestive Authorisation Details. Revestive\u00ae. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/revestive#authorisation-details."},{"key":"ref_13","unstructured":"Electronic Medicines Compendium, EMC (2024, April 18). Summary of Product Characteristics (SmPC). Revestive\u00ae. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/3382\/smpc."},{"key":"ref_14","unstructured":"Refdata (2024, April 18). SAI\u2014Detailed View. Revestive\u00ae. Available online: https:\/\/sai.refdata.ch\/detail\/30994."},{"key":"ref_15","unstructured":"Health Canada. Gouvernement du Canada (2024, April 19). Product Information. Revestive\u00ae. Available online: https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=93100."},{"key":"ref_16","unstructured":"Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica, ANMAT (2024, April 19). Revestive\u00ae. Available online: https:\/\/boletin.anmat.gob.ar\/octubre_2023\/Dispo_8872-23.pdf."},{"key":"ref_17","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria, Anvisa (2024, April 19). Revestive\u00ae (Teduglutide): Expansion of Use, Available online: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/novos-medicamentos-e-indicacoes\/revestive-r-teduglutida-ampliacao-de-uso."},{"key":"ref_18","unstructured":"Instituto de Salud P\u00fablica de Chile, ISPCh (2024, April 22). Prescribing information. Revestive\u00ae. Available online: https:\/\/www.ispch.cl\/sites\/default\/files\/B-2746-19.pdf."},{"key":"ref_19","unstructured":"Pharmaceuticals and Medical Devices Agency, PMDA (2024, April 19). Teduglutide (Genetically Recombinant) General List. Revestive\u00ae. Available online: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/2499419."},{"key":"ref_20","unstructured":"Australian Government, Department of Health, Therapeutic Good Administration, TGA (2024, April 18). Australian Public Assessment Report: Teduglutide. Revestive\u00ae, Available online: https:\/\/www.tga.gov.au\/resources\/auspar\/auspar-teduglutide."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","article-title":"Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2","volume":"76","author":"Drucker","year":"2014","journal-title":"Annu. Rev. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nbt0797-673","article-title":"Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV","volume":"15","author":"Drucker","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/gut.2004.061440","article-title":"Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients","volume":"54","author":"Jeppesen","year":"2005","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/j.gastro.2012.09.007","article-title":"Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure","volume":"143","author":"Jeppesen","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1038\/ctg.2015.69","article-title":"Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome","volume":"7","author":"Schwartz","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ncp.10092","article-title":"Reduction of parenteral nutrition and hydration support and safety with long-term teduglutide treatment in patients with short bowel syndrome-associated intestinal failure: STEPS-3 study","volume":"33","author":"Seidner","year":"2018","journal-title":"Nutr. Clin. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/jpen.1690","article-title":"Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: A 24-week, phase III study","volume":"44","author":"Kocoshis","year":"2020","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/jpen.2061","article-title":"Safety findings in pediatric patients during long-term treatment with teduglutide for short-bowel syndrome-associated intestinal failure: Pooled analysis of 4 clinical studies","volume":"45","author":"Hill","year":"2021","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MPG.0000000000003867","article-title":"Efficacy and safety of teduglutide in infants and children with short bowel syndrome dependent on parenteral support","volume":"77","author":"Chiba","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.12.029","article-title":"Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure","volume":"11","author":"Jeppesen","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00595-022-02587-4","article-title":"Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: Two phase III studies with an extension","volume":"53","author":"Nakamura","year":"2023","journal-title":"Surg. Today"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpeds.2016.10.027","article-title":"Outcomes from a 12-week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome","volume":"181","author":"Carter","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ajcnut.2023.02.019","article-title":"Long-term treatment with teduglutide: A 48-week open-label single-center clinical trial in children with short bowel syndrome","volume":"117","author":"Lambe","year":"2023","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/jpen.1149","article-title":"Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series","volume":"42","author":"Ukleja","year":"2018","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1756284818793343","DOI":"10.1177\/1756284818793343","article-title":"GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting","volume":"11","author":"Schoeler","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jpen.1838","article-title":"Long-Term Outcomes With Teduglutide From a Single Center","volume":"45","author":"Puello","year":"2021","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/jpen.2272","article-title":"Teduglutide in short bowel syndrome patients: A way back to normal life?","volume":"46","author":"Harpain","year":"2022","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clnu.2023.03.012","article-title":"Short-term clinical evaluation of teduglutide for patients with Crohn\u2019s disease on home parenteral support for postoperative short bowel syndrome with intestinal failure","volume":"42","author":"Sato","year":"2023","journal-title":"Clin. Nutr."},{"key":"ref_40","unstructured":"Revestive\u00ae Full Prescribing Information, Shire Pharmaceuticals Ireland Limited. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revestive-epar-product-information_en.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ajcnut.2023.04.009","article-title":"Teduglutide for the treatment of short bowel syndrome: A double-edged sword?","volume":"117","author":"Oliveira","year":"2023","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/gut.2003.035212","article-title":"Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice","volume":"53","author":"Thulesen","year":"2004","journal-title":"Gut"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jpen.1982","article-title":"De novo development of distal jejunal and duodenal adenomas after 41 months of teduglutide treatment in a patient with short-bowel syndrome: A case report","volume":"45","author":"Pevny","year":"2021","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0148607117718480","article-title":"De novo development of hamartomatous duodenal polyps in a patient with short bowel syndrome during teduglutide therapy: A case report","volume":"42","author":"Ukleja","year":"2018","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1136\/gut.2006.091108","article-title":"Guidelines for management of patients with a short bowel","volume":"55","author":"Nightingale","year":"2006","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.clnesp.2022.08.027","article-title":"Long-term results of teduglutide treatment for chronic intestinal failure\u2014Insights from a national, multi-centric patient home-care service program","volume":"51","author":"Greif","year":"2022","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.clnu.2018.07.030","article-title":"Experience with teduglutide treatment for short bowel syndrome in clinical practice","volume":"38","author":"Pevny","year":"2019","journal-title":"Clin. Nutr."},{"key":"ref_48","unstructured":"ClinicalTrials.gov (2023, July 06). Registry for Participants with Short Bowel Syndrome, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01990040."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/jpen.2221","article-title":"Characterization of American teduglutide consumers from 2015 to 2020: A large database study","volume":"46","author":"Loutfy","year":"2022","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clnesp.2021.07.004","article-title":"Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome: An international multicenter survey","volume":"45","author":"Pironi","year":"2021","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"de Dreuille, B., Nuzzo, A., Bataille, J., Mailhat, C., Billiauws, L., Le Gall, M., and Joly, F. (2023). Post-marketing use of teduglutide in a large cohort of adults with short bowel syndrome-associated chronic intestinal failure: Evolution and outcomes. Nutrients, 15.","DOI":"10.3390\/nu15112448"},{"key":"ref_52","unstructured":"GBD 2017 Inflammatory Bowel Disease Collaborators (2020). The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 5, 17\u201330."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562848221078456","article-title":"A review of the therapeutic management of Crohn\u2019s disease","volume":"15","author":"Kumar","year":"2022","journal-title":"Therap Adv. Gastroenterol."},{"key":"ref_54","unstructured":"Revestive (2023, July 11). Summary of product characteristics, Revestive. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/revestive."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"14s","DOI":"10.1177\/0148607113520005","article-title":"Pathophysiology of short bowel syndrome: Considerations of resected and residual anatomy","volume":"38","author":"Tappenden","year":"2014","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.gastro.2017.11.023","article-title":"Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure","volume":"154","author":"Jeppesen","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_57","unstructured":"CDC. Centers for Disease Control and Prevention (2023, October 20). National Center for Health Statistics\u2014ICD-10-CM, Available online: https:\/\/icd10cmtool.cdc.gov\/?fy=FY2024&query=short%20bowel%20syndrome."},{"key":"ref_58","unstructured":"CDC. Centers for Disease Control and Prevention (2023, October 20). Comprehensive Listing ICD-10-CM Files, Available online: https:\/\/www.cdc.gov\/nchs\/icd\/icd-10-cm\/files.html."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/15\/2513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:28:00Z","timestamp":1760110080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/15\/2513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":58,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["nu16152513"],"URL":"https:\/\/doi.org\/10.3390\/nu16152513","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}